Skip to content
OpenCapital
Get started

Verrica Pharmaceuticals Inc. VRCA Q4 2024 Annual earnings

Reported March 11, 2025 · After market close

Revenue$344.0KMiss by $1.8MDiluted EPS-$0.24Beat by $0.01
Revenue estimate$2.1M
EPS estimate-$0.25

Next report

Aug 11, 2026 (In 4 weeks)
Revenue estimate$5.9M
EPS estimate-$0.40

Versus estimates

Revenue

Q1 2026$5.0MBeat by $508.8KQ4 2025$5.1MBeat by $572.0KQ3 2025$14.3MBeat by $9.8MQ2 2025$12.7MBeat by $6.3MQ1 2025$3.4MMiss by $93.7K
Q4 2024$344.0KMiss by $1.8M

Diluted EPS

Q1 2026-$0.41Beat by $0.18Q4 2025-$0.56Miss by $0.13Q3 2025$0.13Beat by $1.27Q2 2025$0.02Beat by $0.72Q1 2025-$1.00Beat by $0.40
Q4 2024-$0.24Beat by $0.01

Ask the moment Verrica Pharmaceuticals Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Verrica Pharmaceuticals Inc. report Q4 2024 earnings?
Verrica Pharmaceuticals Inc. (VRCA) reported Q4 2024 earnings on March 11, 2025 after market close.
What were Verrica Pharmaceuticals Inc.'s Q4 2024 revenue and EPS?
Verrica Pharmaceuticals Inc. reported revenue of $344.0K and diluted EPS of $-0.24 for Q4 2024.
Did Verrica Pharmaceuticals Inc. beat estimates in Q4 2024?
Revenue missed the consensus estimate of $2.1M by $1.8M. EPS beat the consensus estimate of $-0.25 by $0.01.
Where can I find Verrica Pharmaceuticals Inc.'s Q4 2024 SEC filings?
You can read the 10-K periodic report (0000950170-25-037172) directly on SEC EDGAR. The filing index links above go to sec.gov.